Mobile App

Google Play Apple Store
New Directions in the Treatment of Cystic Fibrosis: CFTR Modulator Therapy
Certified CME/CNE/CPE Activity - Mini Modules
The introduction of cystic fibrosis transmembrane regulator (CFTR) modulator therapy represented a true break¬through in overcoming the genetic defects underlying cystic fibrosis (CF). Small-molecule therapy with a single agent, and a combination of that agent with a second complementary agent, has successfully improved meaningful clinical outcomes in patients with specific CF genotypes. This success has led to intensive research and development efforts to expand treatment options to broader populations of CF patients. As new agents become available, clinicians will need to make informed decisions about selecting appropriate therapy for individual CF patients.

These educational Mini Modules will outline the use of current CFTR modulator therapies, expectations for addressing unmet clinical needs with new therapies, and issues around integrating new therapies into clinical practice.
Review one (or all) Mini Modules of interest. Claim AMA, ANCC, or ACPE credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Michael S. Schechter, MD, MPH
Michael S. Schechter, MD, MPH
Professor and Chief
Division of Pulmonary Medicine
Department of Pediatrics
Virginia Commonwealth University
Children’s Hospital of Richmond at VCU


New Directions in the Treatment of Cystic Fibrosis: CFTR Modulator Therapy
Certified CME/CNE/CPE Activity - Mini Modules

Michael S. Schechter, MD, MPH
Michael S. Schechter, MD, MPH
Professor and Chief
Division of Pulmonary Medicine
Department of Pediatrics
Virginia Commonwealth University
Children’s Hospital of Richmond at VCU
The introduction of cystic fibrosis transmembrane regulator (CFTR) modulator therapy represented a true break¬through in overcoming the genetic defects underlying cystic fibrosis (CF). Small-molecule therapy with a single agent, and a combination of that agent with a second complementary agent, has successfully improved meaningful clinical outcomes in patients with specific CF genotypes. This success has led to intensive research and development efforts to expand treatment options to broader populations of CF patients. As new agents become available, clinicians will need to make informed decisions about selecting appropriate therapy for individual CF patients.

These educational Mini Modules will outline the use of current CFTR modulator therapies, expectations for addressing unmet clinical needs with new therapies, and issues around integrating new therapies into clinical practice.
Review one (or all) Mini Modules of interest. Claim AMA, ANCC, or ACPE credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Michael S. Schechter, MD, MPH
Michael S. Schechter, MD, MPH
Professor and Chief
Division of Pulmonary Medicine
Department of Pediatrics
Virginia Commonwealth University
Children’s Hospital of Richmond at VCU





 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.


Overview

The introduction of cystic fibrosis transmembrane regulator (CFTR) modulator therapy represented a true break¬through in overcoming the genetic defects underlying cystic fibrosis (CF). Small-molecule therapy with a single agent, and a combination of that agent with a second complementary agent, has successfully improved meaningful clinical outcomes in patients with specific CF genotypes. This success has led to intensive research and development efforts to expand treatment options to broader populations of CF patients. As new agents become available, clinicians will need to make informed decisions about selecting appropriate therapy for individual CF patients.

These educational Mini Modules will outline the use of current CFTR modulator therapies, expectations for addressing unmet clinical needs with new therapies, and issues around integrating new therapies into clinical practice.

New Directions in the Treatment of Cystic Fibrosis: CFTR Modulator Therapy

Certified CME/CNE/CPE Activity - Mini Modules

Michael S. Schechter, MD, MPH
Michael S. Schechter, MD, MPH
Professor and Chief
Division of Pulmonary Medicine
Department of Pediatrics
Virginia Commonwealth University
Children’s Hospital of Richmond at VCU



20
Supported by an independent educational grant from Vertex Pharmaceuticals
Expired Activity
Mini Module
6179
MiniModules_WebBannerCVCF(1158px).gif
  • Pulmonology
  • Archives
CF
Change Settings